Anxiety Disorders, Depression, Overweight
Conditions
Keywords
Pharmacokinetics, Pharmacodynamics
Brief summary
Volunteers with a prescription of oral sertraline who have been scheduled to bariatric surgery in either Norrköping/Sweden or Lindesberg/Sweden will be asked to participate in a observational study. The aim of this study is to evaluate the absorption and the effect and side effects of sertraline in volunteers 8 weeks before and 1, 6 and 12 months after bariatric surgery.
Detailed description
The pharmacokinetic changes of sertraline after bariatric surgery are studied by assessing the exposition for sertraline in individuals with long term treatment by measuring the area under the curve (AUC0-τ) 8 weeks before and one, six and twelve months after bariatric surgery in 30 participants. The effect of variation of sertraline concentration is studied by a psychiatric assessment of depressive symptoms and symptoms of anxiety disorder. The aim ist to study if there is a relation between changes in pharmacokinetics and effect of sertraline after bariatric surgery. For the assessment of side effects a self-reporting scale is used. These participants are recruited consequentially with the aim to get equal numbers of patients with both most usual types of surgery in Sweden (laparoscopic RYGB and gastric sleeve).
Interventions
None listed
Sponsors
Örebro University, Sweden
Linkoeping University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* scheduled to undergo either gastric bypass or gastric sleeve surgery via surgeon clinics in Örebro or Norrköping * prescription of sertraline * since at least one month * planned to be continued at the time of inclusion * swedish speaking
Exclusion criteria
* comorbidity with the consequence that the potential participant may not be able to complete the study * if participation should result in a high risk for patients health or safety
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Area under the concentration curve of sertraline | 8 weeks before, 1, 6 and 12 month after bariatric surgery before sertraline intake and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 24 hours post dose | Changes in the area under sertraline serum concentration vs time curve (AUC(0-t)) |
| Change in Clinical Anxiety Scale | 8 weeks before, 1, 6 and 12 month after bariatric surgery | Psychiatric assessment of symptoms of anxiety disorders with an 5-items-scale (Psychic tension, Ability to relax/muscular tension, Startle response/hyperarousability, Worrying, Apprehension). Every item has values between 0 (no symptoms) and 4 (marked symptoms). The overall score ranges from 0 to 20.Higher scores indicate higher anxiety symptoms. |
| Change in Montgomery-Åsberg-depression rating scale (MADRS-B) | 8 weeks before, 1, 6 and 12 month after bariatric surgery | Assessment of depressive symptoms with a 10-items scale (Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, Suicidal Thoughts). Higher score indicates more depressive symptoms, each item spans over a score from 0 to 6; the overall score ranges from 0 to 60. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the area under concentration vs time curve of desmethylsertraline | 8 weeks before, 1, 6 and 12 month after bariatric surgerybefore sertraline intake and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 24 hours post dose | Changes in the area under concentration vs time curve of desmethylsertraline |
Countries
Sweden
Outcome results
None listed